FATE (Fate Therapeutics) 6-Month Price Index: 2.05 (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FATE Fate Therapeutics Inc FATE
33 GF Score
Price $2.57
GF Value $0.79
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Fate Therapeutics 6-Month Price Index?

Fate Therapeutics FATE +1.98% 33 6-Month Price Index is 2.05 as of Aug. 16, 2026. GuruFocus rates FATE with a GF Score™ of 33/100 and a GF Value™ of $0.79 (Significantly Overvalued). The stock has 7 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-16), Fate Therapeutics's 6-Month Price Index is 2.05.

Fate Therapeutics  (NAS:FATE) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Fate Therapeutics 6-Month Price Index Related Terms

FATE vs IMRX, NWBO, FHTX: 6-Month Price Index Comparison

For the Biotechnology subindustry, Fate Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FATE
33GF Score
Fate Therapeutics Inc FATE
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fate Therapeutics  (NAS:FATE) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 2.05 mean?
Fate Therapeutics (FATE) has a 6-Month Price Index of 2.05 as of Aug. 16, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Fate Therapeutics and its competitors.
Is Fate Therapeutics' 6-Month Price Index too high?
Fate Therapeutics' current 6-Month Price Index is 2.05. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' 6-Month Price Index compare to IMRX and NWBO?
Fate Therapeutics' 6-Month Price Index of 2.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Fate Therapeutics and its competitors. Fate Therapeutics's current 6-Month Price Index is 2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FATE) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.79, compared to a current price of $2.57 — trading 224.7% above its estimated fair value. The current 6-Month Price Index is 2.05. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Fate Therapeutics (FATE), the current 6-Month Price Index is 2.05 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fate Therapeutics (FATE) Overvalued in 2026?

Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued. The current stock price of $2.57 is trading 224.7% above its estimated GF Value™ of $0.79. GuruFocus considers Fate Therapeutics to be Significantly Overvalued.

Key valuation signals for FATE:

  • 6-Month Price Index: 2.05
  • GF Value™: $0.79 vs. price of $2.57 (224.7% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the FATE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fate Therapeutics Business Description

Other Exchanges F6T:Germany
Address 12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score

Get the complete analysis for FATE

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.57
Price
$0.79
GF Value